GOG 281: Use of Trametinib in Low-Grade Serous Cancer

IJGC Podcast

In this episode of the IJGC podcast, Editor-in-Chief Dr. Pedro Ramirez is joined by Dr. David M. Gershenson to discuss the use of trametinib in low-grade serous cancer. Dr. Gershenson is Professor and former Chair of the Department of Gynecologic Oncology and Reproductive Medicine at The University of Texas MD Anderson Cancer Center. His major focus is on the clinical and translational research of rare ovarian cancers. Highlights: Trametinib represents a new standard for the treatment of recurrent low-grade serous carcinoma of the ovary/peritoneum. The findings of GOG 281 suggest that women whose tumor harbors a MAPK mutation (KRAS, NRAS, BRAF) may have a greater probability of response to trametinib, but the results are hypothesis-generating, and further studies are needed. Importantly, trametinib should not be withheld from a woman whose tumor lacks MAPK mutations.

Based on the findings of GOG 281 and preclinical studies, future trials will include combinations of a MEK inhibitor plus endocrine therapy and novel agents targeting the MAPK signaling pathway or, more specifically, RAS.